Last reviewed · How we verify
NCT04843839
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops
Phase 2 trial testing Nepafenac 0.1% Oph Susp in Congenital Hereditary Endothelial Dystrophy of Cornea in 30 participants. Status unknown.
15 December 2022
Quick facts
| Lead sponsor | L.V. Prasad Eye Institute |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 December 2020 |
| Primary completion | 15 December 2022 |
| Estimated completion | 15 December 2022 |
| Sites | 1 location across India |
Drugs / interventions tested
- Nepafenac 0.1% Oph Susp — full drug profile →
- Refresh Tears 0.5% Lubricant Eye Drops — full drug profile →
Conditions studied
- Congenital Hereditary Endothelial Dystrophy of Cornea — all drugs for Congenital Hereditary Endothelial Dystrophy of Cornea →
Sponsor
L.V. Prasad Eye Institute
Who can join
Under 6, any sex, with Congenital Hereditary Endothelial Dystrophy of Cornea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CHED- Congenital Endothelial Endothelial Dystrophy is a condition that causes corneal cloudiness. Since, currently only surgery is being done to cure this condition, we are taking up the research of using topical eye drops for this condition which is a very simple and easy method. Also, there are no significant side effects to this treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Congenital Hereditary Endothelial Dystrophy: A Review of the Molecular Pathogenesis, Genetic Basis, and Emerging Treatments.
Jomar DE, Khayyat W, Almontashiri NAM, Ahmad K, et al · · 2026 · PMID 41809205 · DOI 10.2147/opth.s553795
Verify or expand the search:
- PubMed search for NCT04843839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nepafenac 0.1% Oph Susp
Trials testing the same drug.
- NCT03406689 — Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections · NA · completed
Other L.V. Prasad Eye Institute trials
Trials by the same sponsor.
- NCT04618510 — SEED-LVPEI Myopia Study · NA · unknown
- NCT06613919 — Six-months Versus Nine-months ATT for Ocular TB · Phase 4 · completed
- NCT03548805 — Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma · NA · completed
- NCT03541551 — Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy · NA · completed
- NCT03230058 — Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04843839 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by L.V. Prasad Eye Institute
- Last refreshed: 14 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04843839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing